Zuzana Tomasik
Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation
Schüpbach J, Daneel S, Staub R, Güntert B, Martinetti G, Andreutti C, Steffen I, Schultze D, Dubs R, Gorgievski M, Matter L, Bürgisser P, Yerly S, Niederhauser C, Tomasik Z, Gebhardt M, Vernazza P. Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation. PLoS medicine 2007; 4:e343.
Dec 1, 2007Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation
Dec 1, 2007PLoS medicine 2007; 4:e343
Schüpbach Jörg, Daneel Synove, Staub Roger, Güntert Bruno, Martinetti Gladys, Andreutti Corinne, Steffen Ingrid, Schultze Detlev, Dubs Rolf, Gorgievski Meri, Matter Lukas, Bürgisser Philippe, Yerly Sabine, Niederhauser Christoph, Tomasik Zuzana, Gebhardt Martin D, Vernazza Pietro
HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
Schüpbach J, Hirschel B, Bernasconi E, Vernazza P, Furrer H, Battegay M, Perrin L, Yerly S, Tomasik Z, Böni J, Fischer M, Joos B, Günthard H, Swiss HIV Cohort Study. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. Journal of acquired immune deficiency syndromes (1999) 2005; 40:250-6.
Nov 1, 2005HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
Nov 1, 2005Journal of acquired immune deficiency syndromes (1999) 2005; 40:250-6
Schüpbach Jörg, Hirschel Bernard, Bernasconi Enos, Vernazza Pietro, Furrer Hansjakob, Battegay Manuel, Perrin Luc, Yerly Sabine, Tomasik Zuzana, Böni Jürg, Fischer Marek, Joos Beda, Günthard Huldrych, Swiss HIV Cohort Study